Full Name
Chng W.J
Chng, W.J.
Chng W.-J.
Chng, Wee Joo
Chng, W.-J.
Main Affiliation


Results 1-20 of 56 (Search time: 0.007 seconds).

Issue DateTitleAuthor(s)
120-Sep-2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisTeoh, Phaik Ju ; An, Omer ; Chung, Tae-Hoon ; Chooi, Jing Yuan ; Toh, Sabrina HM ; Fan, Shuangyi ; Wang, Wilson ; Koh, Bryan TH; Fullwood, Melissa J ; Ooi, Melissa G ; de Mel, Sanjay; Soekojo, Cinnie Y; Chen, Leilei ; Ng, Siok Bian ; Yang, Henry ; Chng, Wee Joo 
22015Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: From molecular pathogenesis to therapeutic targetZhou J. ; Ching Y.Q. ; Chng W.-J. 
328-Apr-2014Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study GroupTse, E.; Chan, T.S.Y.; Koh, L.-P.; Chng, W.-J. ; Kim, W.-S.; Tang, T.; Lim, S.-T.; Lie, A.K.W.; Kwong, Y.-L.
428-Mar-2013ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells.Croxford, J.L. ; Tang, M.L.; Pan, M.F. ; Huang, C.W.; Kamran, N.; Phua, C.M.; Chng, W.J. ; Ng, S.B. ; Raulet, D.H.; Gasser, S. 
511-Jul-2018BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemiaZhou Y.; Zhou J. ; Lu X.; Tan T.-Z. ; Chng W.-J. 
617-Mar-2017Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age SubgroupHeinz Ludwig; Meletios A. Dimopoulos; Philippe Moreau; Wee Joo Chng ; Hartmut Goldschmidt; Roman Hajek; Thierry Facon; Ludek Pour; Ruben Niesvizky; Albert Oriol; Laura Rosinol; Aleksandr Suvorov; Gianluca Gaidano; Tomas Pika; Katja Weisel; Vesselina Goranova-Marinova; Antonio Palumbo; Heidi Gillenwater; Nehal Mohamed; Sanjay Aggarwal; Shibao Feng; Douglas Joshua
722-Sep-2017Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR StudyHartmut Goldschmidt; Philippe Moreau; Heinz Ludwig; Ruben Niesvizky; Wee Joo Chng ; Douglas Joshua; Katja Weisel; Andrew Spencer; Robert Orlowski; Shibao Feng; Karim Iskander; Meletios A. Dimopoulos
8Oct-2009Centrosomes and myeloma; aneuploidy and proliferationChng, W.J. ; Fonseca, R.
92008Clinical and biological significance of RAS mutations in multiple myelomaChng, W.J. ; Van, Wier S.; Fonseca, R.; Gonzalez-Paz, N.; Price-Troska, T.; Rajkumar, S.V.; Kyle, R.A.; Henderson, K.J.; Greipp, P.; Jacobus, S.; Oken, M.M.; Van, Ness B.
102014Clinical profiles of multiple myeloma in asia-an asian myeloma network studyKim, K.; Lee, J.H.; Kim, J.S.; Min, C.K.; Yoon, S.S.; Shimizu, K.; Chou, T.; Kosugi, H.; Suzuki, K.; Chen, W.; Hou, J.; Lu, J.; Huang, X.-J.; Huang, S.-Y.; Chng, W.J. ; Tan, D.; Teoh, G.; Chim, C.S.; Nawarawong, W.; Siritanaratkul, N.; Durie, B.G.
112010Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myelomaChng, W.J. ; Van, Wier S.; Keats, J.J.; Bergsagel, P.L.; Fonseca, R.; Gertz, M.A.; Chung, T.-H. ; Baker, A.; Carpten, J.
12Apr-2012Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivoChan, D.; Tyner, J.W.; Chng, W.J. ; Bi, C.; Okamoto, R.; Said, J.; Ngan, B.D.; Braunstein, G.D.; Koeffler, H.P. 
132009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
1416-Nov-2013Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: Analysis of clinical features and outcomes from the Asia Lymphoma study groupKim, S.J.; Jung, H.A.; Chuang, S.-S.; Hong, H.; Guo, C.-C.; Cao, J.; Hong, X.-N.; Suzuki, R.; Kang, H.J.; Won, J.H.; Chng, W.-J. ; Kwong, Y.-L.; Suh, C.; Song, Y.-Q.; Zhu, J.; Tay, K.; Lim, S.T.; Suzumiya, J.; Lin, T.-Y.; Kim, W.S.
152015Functional characterization of D9, a novel deazaneplanocin a (DZNep) analog, in targeting acute myeloid leukemia (AML)Jiang, Xia; Lim, Cheryl Zi Hui; Li, Zhimei; Lee, Puayleng; Yatim, Siti Maryam J. M.; Guan, Peiyong; Li, Juntao; Zhou, Jianbiao ; Pan, Jingxuan; Chng, Wee Joo ; Chai, Li Lin Christina ; Yu, Qiang 
16Nov-2013Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study GroupKim, S.J.; Hsu, C.; Song, Y.-Q.; Tay, K.; Hong, X.-N.; Cao, J.; Kim, J.S.; Eom, H.S.; Lee, J.H.; Zhu, J.; Chang, K.-M.; Reksodiputro, A.H.; Tan, D.; Goh, Y.T.; Lee, J.; Intragumtornchai, T.; Chng, W.-J. ; Cheng, A.-L.; Lim, S.T.; Suh, C.; Kwong, Y.-L.; Kim, W.S.
172015High-throughput mutation profiling changes before and 3 weeks after chemotherapy in newly diagnosed breast cancer patientsTan S.-H.; Sabrina Sapari N.; Miao H.; Hartman M. ; Loh M.; Chng W.-J. ; Iau P.; Ahmad Buhari S.; Soong R. ; Lee S.-C.
1815-Sep-2019IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple MyelomaChong, Phyllis SY ; Zhou, Jianbiao ; Lim, Julia SL ; Hee, Yan Ting; Chooi, Jing-Yuan ; Chung, Tae-Hoon ; Tan, Zea Tuan ; Zeng, Qi ; Waller, Daniel D; Sebag, Michael; Chng, Wee-Joo 
192014Implications of heterogeneity in multiple myelomaDe Mel S.; Lim S.H.; Tung M.L.; Chng W.-J. 
20Feb-2014IMWG consensus on risk stratification in multiple myelomaChng, W.J. ; Dispenzieri, A.; Chim, C.-S.; Fonseca, R.; Goldschmidt, H.; Lentzsch, S.; Munshi, N.; Palumbo, A.; Miguel, J.S.; Sonneveld, P.; Cavo, M.; Usmani, S.; Durie, B.G.; Avet-Loiseau, H.